Lung Cancer
Conditions
Brief summary
The current study will recruit lung cancer patients to measure tissue protein synthesis rates of non-small cell lung carcinomas and healthy lung tissue. The protein synthesis rates of healthy lung tissue will be compared to lung tumor tissue to establish the remodeling characteristics of healthy versus cancerous lung tissues. We will also examine whether tissue protein synthesis rates of non-small cell lung carcinomas are associated with various tumor- (i.e., size, subclassification) and patient-derived (i.e., inflammation, lung function, smoking status, and smoking history) parameters.
Interventions
OTHERThere are no interventions in the present study
There are no interventions in the present study
Sponsors
Maastricht University Medical Center
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Inclusion criteria
1. Aged 18-65 years 2. Compos mentis 3. Diagnosed with lung cancer, with treatment requiring a thoracotomy or VATS lobectomy
Exclusion criteria
1. Neoadjuvant chemo- or radiotherapy in the past four weeks 2. Use of systemic steroids in the past four week 3. Insulin-dependent diabetes mellitus 4. Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Lung tumor fractional synthetic rate | 5 days prior to surgery | units: % per day |
| Lung tissue fractional synthetic rate | 5 days prior to surgery | units: % per day |
| Muscle tissue fractional synthetic rate | 5 days prior to surgery | units: % per day |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma glucose concentrations | Baseline | units: mmol/L |
| Plasma insulin concentrations | Baseline | units: pmol/L |
| Plasma GH concentrations | Baseline | units: mU/L |
| Plasma IGF-1 concentrations | Baseline | units: nmol/L |
| Plasma IGFBP-1 concentrations | Baseline | units: ug/L |
| Plasma IGFBP-3 concentrations | Baseline | units: ug/L |
| Plasma CRP concentrations | Baseline | units: mg/L |
| Plasma IL-1 concentrations | Baseline | units: ng/L |
| Plasma IL-6 concentrations | Baseline | units: ng/L |
| Plasma IL-10 concentrations | Baseline | units: ng/L |
| Plasma TNF-alpha concentrations | Baseline | units: ng/L |
Countries
Netherlands
Contacts
Primary ContactAndrew Holwerda, PhD
Outcome results
None listed